1
|
Finnegan P, Murphy M, Bourke J. The use of dual biologic therapy for the management of recalcitrant psoriasis. JAAD Case Rep 2024; 47:93-95. [PMID: 38689867 PMCID: PMC11058710 DOI: 10.1016/j.jdcr.2024.02.036] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/02/2024] Open
Affiliation(s)
- Paula Finnegan
- Department of Dermatology, South Infirmary Victoria University Hospital, Cork, Ireland
| | - Michelle Murphy
- Department of Dermatology, South Infirmary Victoria University Hospital, Cork, Ireland
| | - John Bourke
- Department of Dermatology, South Infirmary Victoria University Hospital, Cork, Ireland
| |
Collapse
|
2
|
Hren MG, Guenin S, Khattri S. Use of dual biologic therapy targeting the Th2 and Th17 axes simultaneously to treat patients with atopic dermatitis and concomitant psoriasis, psoriatic arthritis, or inflammatory bowel disease. J Am Acad Dermatol 2024:S0190-9622(24)00492-4. [PMID: 38494153 DOI: 10.1016/j.jaad.2024.03.007] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/10/2024] [Revised: 03/04/2024] [Accepted: 03/06/2024] [Indexed: 03/19/2024]
Affiliation(s)
- Mary Grace Hren
- Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, New York; Renaissance School of Medicine, Stony Brook University, Stony Brook, New York
| | - Sophie Guenin
- Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, New York; New York Medical College, Valhalla, New York
| | - Saakshi Khattri
- Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, New York.
| |
Collapse
|
3
|
Carriera L, Fantò M, Martini A, D’Abramo A, Puzio G, Scaramozzino MU, Coppola A. Combination of Biological Therapy in Severe Asthma: Where We Are? J Pers Med 2023; 13:1594. [PMID: 38003909 PMCID: PMC10672189 DOI: 10.3390/jpm13111594] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/22/2023] [Revised: 11/06/2023] [Accepted: 11/08/2023] [Indexed: 11/26/2023] Open
Abstract
Biological drugs have revolutionized the management of severe asthma. However, a variable number of patients remain uncontrolled or only partially controlled even after the appropriate administration of a biologic agent. The combination of two biologics may target different inflammatory pathways, and it has been used in patients suffering from uncontrolled severe asthma with evidence of both allergic and eosinophilic phenotypes or severe asthma and type2 comorbidities. Combination therapy has also been used to handle anti-IL4/13R induced hypereosinophilia. There is insufficient data on combining biologics for the treatment of severe uncontrolled asthma and type 2 comorbidities, also because of the high cost, and currently no guideline recommends dual biologic therapy. A systematic search was performed using the Medline and Scopus databases. Published data on concurrent administration of two biological drugs in severe, uncontrolled asthma patients has been reported in 28 real-world studies and 1 clinical trial. Data extraction was followed by a descriptive and narrative synthesis of the findings. Future studies should be conducted to further assess the safety, efficacy, and cost-effectiveness of this therapeutic strategy.
Collapse
Affiliation(s)
- Lorenzo Carriera
- Facoltà di Medicina e Chirurgia, Università Cattolica del Sacro Cuore, 00168 Rome, Italy;
| | - Marta Fantò
- UOSD Allergologia e Immunologia Clinica, A.O. San Donato, USL Toscana Sud Est, 52100 Arezzo, Italy;
| | - Alessia Martini
- Facoltà di Medicina e Chirurgia, Università Cattolica del Sacro Cuore, 00168 Rome, Italy;
| | - Alice D’Abramo
- UOC Pneumologia, Ospedale San Filippo Neri-ASL Roma 1, 00135 Rome, Italy; (A.D.); (G.P.); (A.C.)
| | - Genesio Puzio
- UOC Pneumologia, Ospedale San Filippo Neri-ASL Roma 1, 00135 Rome, Italy; (A.D.); (G.P.); (A.C.)
| | | | - Angelo Coppola
- UOC Pneumologia, Ospedale San Filippo Neri-ASL Roma 1, 00135 Rome, Italy; (A.D.); (G.P.); (A.C.)
- UniCamillus, Saint Camillus International University of Health Sciences, 00131 Rome, Italy
| |
Collapse
|
4
|
Solitano V, Ma C, Hanžel J, Panaccione R, Feagan BG, Jairath V. Advanced Combination Treatment With Biologic Agents and Novel Small Molecule Drugs for Inflammatory Bowel Disease. Gastroenterol Hepatol (N Y) 2023; 19:251-263. [PMID: 37799456 PMCID: PMC10548249] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/07/2023]
Abstract
The use of combination therapy with a biologic agent and immunosuppressant has well-established efficacy and safety and is common practice in the management of inflammatory bowel disease (IBD). Current research has shifted focus toward the use of advanced combination treatment (ACT). This term was coined to describe combination therapy using 2 or more advanced treatments (biologic agents and/or oral small molecule drugs) with the aim of achieving optimal disease control in selected patients. An ACT approach may be particularly beneficial in patients with documented medically refractory IBD and in patients with a poor prognosis, extraintestinal manifestations, or concomitant immune-mediated inflammatory diseases. To date, the body of evidence for ACT strategies in IBD is largely comprised of uncontrolled retrospective case series and cohort studies in highly refractory patients. Recently, results from the VEGA trial have suggested that combination induction therapy with guselkumab and golimumab was more effective in ulcerative colitis than either agent alone. However, questions remain about issues such as related costs, ACT duration, and optimal combinations to adopt. Future randomized controlled trials are likely to evaluate rationally selected combinations of agents. This article summarizes the available literature on ACT, including comparisons with traditional combination therapy and the rheumatology field, and discusses practical recommendations, profiles of IBD patients who should be considered for combination approaches in clinical practice, and remaining knowledge gaps.
Collapse
Affiliation(s)
- Virginia Solitano
- Division of Gastroenterology, Department of Medicine, Western University, London, Ontario, Canada
- Alimentiv, London, Ontario, Canada
- Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy
| | - Christopher Ma
- Alimentiv, London, Ontario, Canada
- Division of Gastroenterology & Hepatology, Department of Medicine, University of Calgary, Calgary, Alberta, Canada
- Department of Community Health Sciences, University of Calgary, Calgary, Alberta, Canada
| | - Jurij Hanžel
- Alimentiv, London, Ontario, Canada
- Department of Gastroenterology and Hepatology, University Medical Center Ljubljana and Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia
| | - Remo Panaccione
- Division of Gastroenterology & Hepatology, Department of Medicine, University of Calgary, Calgary, Alberta, Canada
| | - Brian G. Feagan
- Division of Gastroenterology, Department of Medicine, Western University, London, Ontario, Canada
- Alimentiv, London, Ontario, Canada
- Department of Epidemiology and Biostatistics, Western University, London, Ontario, Canada
| | - Vipul Jairath
- Division of Gastroenterology, Department of Medicine, Western University, London, Ontario, Canada
- Alimentiv, London, Ontario, Canada
- Department of Epidemiology and Biostatistics, Western University, London, Ontario, Canada
| |
Collapse
|
5
|
Diluvio L, Pensa C, Piccolo A, Lanna C, Bianchi L, Campione E. Coesisting inflammatory skin diseases: Tildrakizumab to control psoriasis and Omalizumab for urticaria. Dermatol Ther 2022; 35:e15359. [PMID: 35138022 DOI: 10.1111/dth.15359] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/25/2021] [Revised: 12/24/2021] [Accepted: 02/03/2022] [Indexed: 11/29/2022]
Abstract
In Western countries the number of individuals suffering from an autoimmune condition is constantly growing and often patients suffering from autoimmune disease are susceptible to developing a second autoimmune disorder. We report a case of an adult female patient affected by psoriasis vulgaris and treated with tildrakizumab, a humanized monoclonal antibody targeting interleukin-23, who later developed chronic spontaneous urticaria and started omalizumab, a humanized antibody to IgE, showing a favorable outcome. We speculate that the two combined therapies have restored the cytokine balance bringing it towards tolerance and remission of the two pathologies. It is conceivable that tildrakizumab may have a synergic action with omalizumab in the treatment of urticaria in patients affected by both psoriasis and urticaria. Our case and the study of the mechanisms of action of the two drugs suggest how the two therapies can act with an interlocking mechanism in achieving the final therapeutic effect.
Collapse
Affiliation(s)
- Laura Diluvio
- Department of Dermatology, University of Rome Tor Vergata, Viale Oxford, Rome, Italy
| | - Chiara Pensa
- Department of Dermatology, University of Rome Tor Vergata, Viale Oxford, Rome, Italy
| | - Arianna Piccolo
- Department of Dermatology, University of Rome Tor Vergata, Viale Oxford, Rome, Italy
| | - Caterina Lanna
- Department of Dermatology, University of Rome Tor Vergata, Viale Oxford, Rome, Italy
| | - Luca Bianchi
- Department of Dermatology, University of Rome Tor Vergata, Viale Oxford, Rome, Italy
| | - Elena Campione
- Department of Dermatology, University of Rome Tor Vergata, Viale Oxford, Rome, Italy
| |
Collapse
|
6
|
Yang E, Panaccione N, Whitmire N, Dulai PS, Vande Casteele N, Singh S, Boland BS, Collins A, Sandborn WJ, Panaccione R, Battat R. Efficacy and safety of simultaneous treatment with two biologic medications in refractory Crohn's disease. Aliment Pharmacol Ther 2020; 51:1031-1038. [PMID: 32329532 PMCID: PMC8032452 DOI: 10.1111/apt.15719] [Citation(s) in RCA: 72] [Impact Index Per Article: 18.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/18/2020] [Revised: 02/09/2020] [Accepted: 03/21/2020] [Indexed: 12/20/2022]
Abstract
BACKGROUND Biologic therapies in patients with Crohn's disease often yield low clinical and endoscopic remission rates. After multiple failed therapies, combining two biologic therapies is possibly the sole medical alternative to recurrent surgery. However, data on this approach are limited. AIMS To assess the efficacy and safety of concomitant use of two biologic therapies in the largest cohort to date of refractory Crohn's disease patients. METHODS Data were extracted from Crohn's disease patients started on dual biologic therapy at two referral centres. Biologics utilised include infliximab, adalimumab, vedolizumab, ustekinumab, certolizumab and golimumab. The primary outcome was endoscopic improvement (>50% reduction in Simplified Endoscopic Score-Crohn's disease [SES-CD] or explicitly stated). Endoscopic remission (SES-CD < 3 or stated), clinical response (Crohn's disease-patient-reported outcome-2 score [PRO2] reduced by 8), clinical remission (PRO2 < 8), and C-reactive protein (CRP) were also assessed. RESULTS A total of 22 patients with 24 therapeutic trials of dual biologic therapy were identified. The majority of patients had prior surgical resections (91%), stricturing (59%) or penetrating (36%) phenotype, and perianal fistulas (50%). Median number of prior failed biologics was 4. Endoscopic improvement occurred in 43% of trials and 26% achieved endoscopic remission. Fifty per cent had clinical response and 41% achieved clinical remission. There were significant post-treatment reductions in median SES-CD (14.0 [12.0-17.5] to 6.0 [2.5-8.0], P = 0.0005], PRO-2 (24.1 [20.3-27.0] to 13.4 [4.6-21.8], P = 0.002] and CRP (17.0 [11.0-24.0] to 9.0 [4.0-14.0], P = 0.02). Presence of perianal fistulas decreased from 50% to 33%. Adverse events occurred in 13% of trials. CONCLUSION Dual biologic therapy was associated with clinical, biomarker and endoscopic improvements in selected patients with refractory Crohn's disease who failed multiple biologics. Further studies are needed to validate this approach.
Collapse
Affiliation(s)
- Edward Yang
- UCSD Inflammatory Bowel Disease Center, Division of Gastroenterology, Department of Medicine, 9500 Gilman Drive, La Jolla, California 92093
| | - Nicola Panaccione
- Faculty of Health Science, Western University, 1151 Richmond Street, London, Ontario, Canada
| | - Natalie Whitmire
- UCSD Inflammatory Bowel Disease Center, Division of Gastroenterology, Department of Medicine, 9500 Gilman Drive, La Jolla, California 92093
| | - Parambir S. Dulai
- UCSD Inflammatory Bowel Disease Center, Division of Gastroenterology, Department of Medicine, 9500 Gilman Drive, La Jolla, California 92093
| | - Niels Vande Casteele
- UCSD Inflammatory Bowel Disease Center, Division of Gastroenterology, Department of Medicine, 9500 Gilman Drive, La Jolla, California 92093
| | - Siddharth Singh
- UCSD Inflammatory Bowel Disease Center, Division of Gastroenterology, Department of Medicine, 9500 Gilman Drive, La Jolla, California 92093
| | - Brigid S. Boland
- UCSD Inflammatory Bowel Disease Center, Division of Gastroenterology, Department of Medicine, 9500 Gilman Drive, La Jolla, California 92093
| | - Angelina Collins
- UCSD Inflammatory Bowel Disease Center, Division of Gastroenterology, Department of Medicine, 9500 Gilman Drive, La Jolla, California 92093
| | - William J. Sandborn
- UCSD Inflammatory Bowel Disease Center, Division of Gastroenterology, Department of Medicine, 9500 Gilman Drive, La Jolla, California 92093
| | - Remo Panaccione
- University of Calgary Inflammatory Bowel Disease Center, Division of Gastroenterology, Department of Medicine, 3280 Hospital Drive NW, Calgary, Alberta
| | - Robert Battat
- UCSD Inflammatory Bowel Disease Center, Division of Gastroenterology, Department of Medicine, 9500 Gilman Drive, La Jolla, California 92093,Weill Cornell Jill Roberts Center for Inflammatory Bowel Disease, Division of Gastroenterology and Hepatology, Department of Medicine, 1283 York Avenue, 9th Floor, New York, New York 10065
| |
Collapse
|
7
|
Affiliation(s)
- Quinn Thibodeaux
- Correspondence to: Quinn Thibodeaux, MD, UCSF Psoriasis and Skin Treatment Center, 515 Spruce Street, San Francisco, CA 94118.
| | | | | | | | | |
Collapse
|